FY2025 · ended Dec 31, 2025 · Revenue $12.59M, +3292.5% YoY · Filed Mar 26, 2026
Spero Therapeutics, Inc. (SPRO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $12.6 million and net income of $8.6 million. As of Jun 30, 2026 it held $50.8 million in cash and investments and $2.0 million in total debt.
Revenue (TTM)
$12.57M
+9647.3% vs year-ago TTM
Net income (TTM)
$7.38M
+113.8% vs year-ago TTM
Operating cash flow (TTM)
$19.58M
+160.6% vs year-ago TTM
Free cash flow
$-86.03M
-70.9% vs prior year
EPS (TTM)
$0.12
+112.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
57.89M
+3.6% vs prior year
Net cash
$48.73M
as of Jun 30, 2026
Operating margin
47.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SPRO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1701108
- Former names
- Spero Therapeutics, LLC (until Mar 21, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $12.6M | $371,000 | $933,000 | $2.5M | $3.1M |
| Operating income | $6.3M | -$73.4M | $21.5M | -$42.2M | -$88.0M |
| Net income | $8.6M | -$68.6M | — | — | -$89.8M |
| Diluted EPS | $0.15 | -$1.27 | $0.43 | -$1.23 | — |
| Operating cash flow | -$12.6M | -$23.4M | -$33.0M | -$7.7M | -$64.3M |
| Total assets | $68.9M | $110.5M | $182.4M | $124.8M | $171.1M |
| Total liabilities | $9.9M | $64.4M | $75.5M | $48.9M | $82.8M |
| Stockholders' equity | $59.0M | $46.1M | $106.9M | $75.9M | $88.3M |
| Cash and investments | $40.3M | $52.9M | $76.3M | $109.1M | $146.4M |
| Total debt | $2.9M | $4.3M | $5.5M | $6.6M | $7.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 27, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Aug 28, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure, Other events
|
Jul 14, 2026 | Jul 8, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 25, 2026 | Jun 23, 2026 |
All 515 Spero Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.